- Cipla reported a first-quarter net income of 13 billion rupees, which is a 10% increase compared to the previous year.
- The net income surpassed analysts’ estimates, which were set at 11.99 billion rupees.
- Revenue for the quarter was 69.6 billion rupees, marking a 4% year-on-year growth.
- The reported revenue fell short of the estimate, which was 70.57 billion rupees.
- Total costs for the quarter amounted to 54.5 billion rupees, also up by 4% from the previous year.
- Other income showed a significant increase, rising by 62% to 2.59 billion rupees.
- Market analyst recommendations include 25 buys, 7 holds, and 8 sells for Cipla’s stock.
Cipla Ltd on Smartkarma
On Smartkarma, analyst Brian Freitas shared insights on Cipla Ltd in his report titled “India: Potential Free Float Changes & Passive Flows in 3 Weeks.” The report discusses how changes to shareholding patterns could impact the float of certain stocks in local and global indices. Companies in India disclosed their shareholding pattern as of end-March in April, revealing significant float changes from previous periods.
According to Freitas, these changes in free float could influence domestic and global indices in the coming weeks and months, prompting action from passive trackers. The report suggests that 6 stocks may experience passive inflows from global trackers, while 4 could see passive outflows in May, indicating potential market movements for Cipla Ltd and other companies affected by these dynamics.
A look at Cipla Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 4.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts using Smartkarma’s Smart Scores for Cipla Ltd have identified a positive long-term outlook for the pharmaceutical company. Cipla Ltd has received strong scores across various factors, with particularly high marks in resilience, dividend, and growth. The company’s consistent performance and ability to weather market challenges have earned it a top score in resilience, indicating its stability in uncertain times.
Furthermore, Cipla Ltd‘s robust dividend and growth scores highlight its potential for generating returns for investors while continuing to expand its operations. With solid momentum in its business activities, Cipla Ltd appears well-positioned for future growth and value creation in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
